GH Research (GHRS)

• Market cap: $1.87B
• 1 day: -1.27%
• 5 days: -4.82%
• 1 month: 10.89%
• 3 months: 34.72%
• 6 months: 64.34%
• Year to date: 106.04%
• 1 year: 88.27%
• 5 years: 63.06%
• 10 years: 41.71%
• Sector: Healthcare
• Industry: Biotechnology

About: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Employees: 73